Medicare

Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season

Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as 100,000+ Patients Seek Affordable Semaglutide...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...

Trumps Marijuana Reclassification is Only the Beginning: Why MMJ International Holdings Takes the Lead in the Medicare and Research Reset

"Federal Marijuana Reform Is Coming-But FDA-Ready Companies Will Benefit the most" Duane Boise CEO MMJ International Holdings stated. WASHINGTON, DC...

ZeOmega Recognized in 2025 Gartner(R) Market Guide for U.S. Healthcare Payer Care Management Workflow Applications

ZeOmega believes that this designation underscores its differentiation in modernizing payer care management amid rising interoperability and AI-related regulatory demands...

Matt Kazan, former Senate Finance advisor, returns to Avalere Health as Senior Vice President, Policy, and Laura Housman elevates to Chief Public Health Officer

Kazan will take Avalere Health's prestigious policy offering to new heights while Housman will infuse biopharma brands with evolving public...

Matt Kazan, former Senate Finance advisor, returns to Avalere Health as Senior Vice President, Policy, and Laura Housman elevates to Chief Public Health Officer

Kazan will take Avalere Health's prestigious policy offering to new heights while Housman will infuse biopharma brands with evolving public...

error: Content is protected !!